LifeMD (LFMD) to Release Earnings on Monday

LifeMD (NASDAQ:LFMD) is expected to be releasing its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect LifeMD to post earnings of ($0.01) per share and revenue of $48.5720 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

LifeMD Trading Down 4.0%

LifeMD stock opened at $2.67 on Monday. LifeMD has a 1-year low of $2.56 and a 1-year high of $15.84. The firm has a market capitalization of $128.53 million, a PE ratio of -15.71 and a beta of 1.92. The firm’s 50 day simple moving average is $3.36 and its 200 day simple moving average is $4.72.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. KeyCorp lowered their price objective on LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 19th. BTIG Research lowered their price target on LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. HC Wainwright cut their price objective on LifeMD from $13.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, November 19th. Mizuho lowered their target price on shares of LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 19th. Finally, Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, LifeMD presently has a consensus rating of “Moderate Buy” and an average price target of $9.25.

Insiders Place Their Bets

In other LifeMD news, CMO Jessica Friedeman sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $3.61, for a total value of $54,150.00. Following the completion of the sale, the chief marketing officer owned 205,000 shares of the company’s stock, valued at $740,050. This represents a 6.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 18.40% of the stock is owned by insiders.

Institutional Investors Weigh In On LifeMD

A number of hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of LifeMD in the 4th quarter valued at $36,000. Jain Global LLC bought a new stake in LifeMD in the fourth quarter worth $45,000. Quarry LP purchased a new stake in LifeMD during the third quarter valued at about $52,000. Tower Research Capital LLC TRC grew its stake in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after buying an additional 2,452 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of LifeMD by 18.8% in the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock worth $83,000 after buying an additional 3,870 shares during the period. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.